Moreover, NEDD9 overexpression predicts poor clinical outcome in AML and might act as a potential biomarker guiding treatment selection between chemotherapy and hematopoietic stem cell transplantation (HSCT) as consolidation therapy. This evidence concerns the gene NEDD9 and acute myeloid leukemia.